The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Gregory Russell Pond
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Acceleron Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Horizon Pharma; Inovio Pharmaceuticals; Lilly; Novartis; Pfizer
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
Guenter Niegisch
Consulting or Advisory Role - Bristol-Myers Squibb; IMS Health; Roche Pharma AG
Research Funding - 4SC
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Pfizer; Roche
 
Evan Y. Yu
Consulting or Advisory Role - AstraZeneca; Bayer; Churchill Pharmaceuticals; Dendreon; EMD Serono; Ferring; Genentech/Roche; Janssen; Lilly; Merck
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Lilly/ImClone (Inst); Merck (Inst)
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Aristotelis Bamias
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Pierre Fabre
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Neeraj Agarwal
Consulting or Advisory Role - Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Eisai; Roche
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst)
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche; medivation; Novartis; pfizer
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Simon J. Crabb
Honoraria - Astellas Pharma; Clovis Oncology; Janssen; Novartis; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Roche; Sanofi
Research Funding - Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Plexxikon
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Merck; Roche
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Daniel W. Bowles
No Relationships to Disclose
 
Dominik R. Berthold
No Relationships to Disclose
 
Christine Theodore
No Relationships to Disclose
 
Srikala S. Sridhar
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Sanofi (Inst)
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EMD Serono; Inovio Pharmaceuticals; Lilly; Merck; Roche/Genentech; Sanofi; Seagen
Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck